Allakos (ALLK) News Today $0.23 +0.00 (+1.69%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$0.24 +0.00 (+0.13%) As of 03/27/2025 06:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 Time Period Acerus Pharmaceuticals (OTCMKTS:TRLPF) and Allakos (NASDAQ:ALLK) Head to Head ContrastMarch 20, 2025 | americanbankingnews.comAllakos Inc.: Hold Rating Amid Restructuring and Financial UncertaintyMarch 17, 2025 | tipranks.comAllakos faces potential Nasdaq delisting over share priceMarch 15, 2025 | investing.comAllakos Reports Q4 2024 Results Amid Strategic ShiftMarch 14, 2025 | tipranks.comAllakos Inc.: Allakos Provides Business Update and Reports Fourth Quarter 2024 Financial ResultsMarch 13, 2025 | finanznachrichten.deAllakos reports Q4 EPS 0c, consensus (18c)March 13, 2025 | msn.comAllakos Provides Business Update and Reports Fourth Quarter 2024 Financial ResultsMarch 12, 2025 | globenewswire.comLycia Therapeutics Announces the Appointment of Chin Lee, MD, MPH, as Chief Medical Officer and Reveals Immunology PipelineFebruary 11, 2025 | globenewswire.comKuehn Law Encourages Investors of Allakos Inc. to Contact Law FirmFebruary 10, 2025 | globenewswire.comAllakos Faces Strategic Uncertainty Following AK006 Phase 1 Trial Failure and Workforce ReductionJanuary 29, 2025 | markets.businessinsider.comAllakos cuts 75% of workforce after chronic hives trial failureJanuary 28, 2025 | finance.yahoo.comHold Rating on Allakos Amid Clinical and Financial Setbacks with AK006January 28, 2025 | markets.businessinsider.comAllakos downgraded to Market Perform from Outperform at JMP SecuritiesJanuary 28, 2025 | markets.businessinsider.comAllakos Shares Plummet to All-Time Low After Lead Candidate FailureJanuary 28, 2025 | marketwatch.comBay Area biotech firm Allakos, once worth $13B, lays off most of remaining workersJanuary 28, 2025 | msn.comAllakos To Drop Clinical Development Of AK006, Cut 75% Workforce; Stock Tanks In Pre-MarketJanuary 28, 2025 | markets.businessinsider.comAllakos to discontinue further clinical development of AK006, cut workforce 75%January 28, 2025 | markets.businessinsider.comAllakos stock hits 52-week low at $0.3 amid market challengesJanuary 28, 2025 | msn.comAllakos shares fall as Jefferies cuts price target to $0.40January 28, 2025 | msn.comWhy Is Allakos Stock Plunging On Monday?January 27, 2025 | benzinga.comAllakos Drops AK006, Cuts 75% of Staff After Study FailureJanuary 27, 2025 | marketwatch.comAllakos stock tumbles following AK006 trial discontinuationJanuary 27, 2025 | au.investing.comAllakos Restructures Amid AK006 Discontinuation and LayoffsJanuary 27, 2025 | tipranks.comAllakos Announces Topline Results from its Phase 1 Trial of AK006 in Patients with Chronic Spontaneous Urticaria and Announces RestructuringJanuary 27, 2025 | globenewswire.comDiscover US Penny Stocks To Watch In January 2025January 22, 2025 | uk.finance.yahoo.comJMP Securities healthcare analysts hold an analyst/industry conference callJanuary 8, 2025 | markets.businessinsider.comPromising Outlook for Allakos’s AK006 in Treating Chronic Spontaneous Urticaria Justifies Buy RatingJanuary 8, 2025 | markets.businessinsider.comShort Interest in Allakos Inc. (NASDAQ:ALLK) Drops By 15.7%Allakos Inc. (NASDAQ:ALLK - Get Free Report) was the target of a significant drop in short interest during the month of December. As of December 15th, there was short interest totalling 842,800 shares, a drop of 15.7% from the November 30th total of 1,000,000 shares. Based on an average daily trading volume, of 656,500 shares, the short-interest ratio is currently 1.3 days.December 29, 2024 | marketbeat.comKuehn Law Encourages Investors of Allakos Inc. to Contact Law FirmDecember 19, 2024 | prnewswire.comPromising Potential of Allakos’s AK006 Drives Buy Rating Amidst Market Interest in Chronic Spontaneous UrticariaDecember 17, 2024 | markets.businessinsider.comFmr LLC Increases Stock Holdings in Allakos Inc. (NASDAQ:ALLK)Fmr LLC lifted its stake in Allakos Inc. (NASDAQ:ALLK - Free Report) by 14.6% in the third quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 5,370,247 shares of the company's stock after purchasing an additional 685,623 shares during the quarter. Fmr LLC oDecember 14, 2024 | marketbeat.comPoint72 Asset Management L.P. Purchases New Position in Allakos Inc. (NASDAQ:ALLK)Point72 Asset Management L.P. acquired a new stake in shares of Allakos Inc. (NASDAQ:ALLK - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 1,750,000 shares of the company's stock, valued at aDecember 11, 2024 | marketbeat.comKuehn Law Encourages Investors of Allakos Inc. to Contact Law FirmDecember 9, 2024 | markets.businessinsider.comAllakos Reports Q3 2024 Results and Research ProgressNovember 22, 2024 | markets.businessinsider.comAllakos Inc. Alters Lease Agreement for Cost SavingsNovember 19, 2024 | markets.businessinsider.comLeerink Partnrs Increases Earnings Estimates for AllakosAllakos Inc. (NASDAQ:ALLK - Free Report) - Leerink Partnrs upped their FY2024 earnings estimates for Allakos in a note issued to investors on Thursday, November 7th. Leerink Partnrs analyst T. Smith now forecasts that the company will earn ($1.19) per share for the year, up from their prior estimNovember 11, 2024 | marketbeat.comAllakos (ALLK) Gets a Hold from TD CowenNovember 8, 2024 | markets.businessinsider.comAllakos (ALLK) Gets a Sell from BarclaysNovember 8, 2024 | markets.businessinsider.comAllakos Runs Up Into A Near-Term CatalystNovember 7, 2024 | seekingalpha.comAllakos Provides Business Update and Reports Third Quarter 2024 Financial ResultsNovember 6, 2024 | globenewswire.comAllakos Inc. (NASDAQ:ALLK) Short Interest Down 17.1% in OctoberAllakos Inc. (NASDAQ:ALLK - Get Free Report) was the target of a significant drop in short interest in the month of October. As of October 15th, there was short interest totalling 1,650,000 shares, a drop of 17.1% from the September 30th total of 1,990,000 shares. Based on an average trading volume of 547,900 shares, the short-interest ratio is currently 3.0 days.October 28, 2024 | marketbeat.comAllakos (NASDAQ:ALLK) Stock Quotes, Forecast and News SummaryOctober 24, 2024 | benzinga.comAnalysts Conflicted on These Healthcare Names: Allakos (ALLK), Edwards Lifesciences (EW) and NewAmsterdam Pharma Company (NAMS)October 14, 2024 | markets.businessinsider.comPiper Sandler Sticks to Its Buy Rating for Allakos (ALLK)October 13, 2024 | markets.businessinsider.comAllakos Inc.: Allakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy VolunteersOctober 12, 2024 | finanznachrichten.deLifeSci Capital Reaffirms Their Hold Rating on Allakos (ALLK)October 12, 2024 | markets.businessinsider.comTD Cowen Sticks to Their Hold Rating for Allakos (ALLK)October 12, 2024 | markets.businessinsider.comAllakos perks up after early-stage data for lead assetOctober 12, 2024 | msn.comAllakos Announces Phase 1 Trial Results of Subcutaneous AK006 in Healthy VolunteersOctober 10, 2024 | globenewswire.comThird Harmonic Bio: Nothing Stands OutOctober 7, 2024 | seekingalpha.com Remove Ads Get Allakos News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLK Media Mentions By Week ALLK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ALLK News Sentiment▼1.430.78▲Average Medical News Sentiment ALLK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ALLK Articles This Week▼21▲ALLK Articles Average Week Remove Ads Get Allakos News Delivered to You Automatically Sign up to receive the latest news and ratings for ALLK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Climb Bio News Today Vigil Neuroscience News Today Zura Bio News Today Invivyd News Today SELLAS Life Sciences Group News Today Adlai Nortye News Today Rani Therapeutics News Today Cabaletta Bio News Today Vistagen Therapeutics News Today HilleVax News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ALLK) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon Musk is helping print “new gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Allakos Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Allakos With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ALLK Stock Free ALLK Stock Alerts